GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Cyclically Adjusted PB Ratio

Enlivex Therapeutics (FRA:1BT) Cyclically Adjusted PB Ratio : 0.06 (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Enlivex Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-23), Enlivex Therapeutics's current share price is €1.31. Enlivex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €21.13. Enlivex Therapeutics's Cyclically Adjusted PB Ratio for today is 0.06.

The historical rank and industry rank for Enlivex Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:1BT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.17
Current: 0.06

During the past years, Enlivex Therapeutics's highest Cyclically Adjusted PB Ratio was 0.17. The lowest was 0.00. And the median was 0.00.

FRA:1BT's Cyclically Adjusted PB Ratio is ranked better than
91.71% of 651 companies
in the Biotechnology industry
Industry Median: 1.74 vs FRA:1BT: 0.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enlivex Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was €1.483. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €21.13 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enlivex Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Enlivex Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Cyclically Adjusted PB Ratio Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.16 0.11

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.14 0.10 0.06 0.11

Competitive Comparison of Enlivex Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Enlivex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Cyclically Adjusted PB Ratio falls into.



Enlivex Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Enlivex Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.31/21.13
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enlivex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Enlivex Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.483/129.4194*129.4194
=1.483

Current CPI (Dec. 2023) = 129.4194.

Enlivex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.000 99.695 0.000
201406 7.792 100.560 10.028
201409 72.841 100.428 93.869
201412 69.926 99.070 91.348
201503 72.971 99.621 94.798
201506 62.941 100.684 80.905
201509 55.369 100.392 71.379
201512 46.273 99.792 60.011
201603 50.936 100.470 65.612
201606 33.634 101.688 42.806
201609 24.725 101.861 31.414
201612 20.125 101.863 25.569
201703 14.302 102.862 17.995
201706 10.060 103.349 12.598
201709 7.523 104.136 9.350
201712 6.395 104.011 7.957
201803 0.000 105.290 0.000
201806 3.179 106.317 3.870
201809 0.000 106.507 0.000
201812 19.192 105.998 23.433
201903 1.207 107.251 1.456
201906 1.344 108.070 1.610
201909 1.211 108.329 1.447
201912 0.983 108.420 1.173
202003 2.161 108.902 2.568
202006 1.991 108.767 2.369
202009 1.797 109.815 2.118
202012 2.000 109.897 2.355
202103 4.158 111.754 4.815
202106 4.090 114.631 4.618
202109 4.085 115.734 4.568
202112 4.106 117.630 4.518
202203 3.838 121.301 4.095
202206 3.525 125.017 3.649
202209 3.471 125.227 3.587
202212 2.913 125.222 3.011
202303 2.544 127.348 2.585
202306 2.201 128.729 2.213
202309 1.954 129.860 1.947
202312 1.483 129.419 1.483

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enlivex Therapeutics  (FRA:1BT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Enlivex Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics (FRA:1BT) Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (FRA:1BT) Headlines

No Headlines